Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P; Olesoxime SMA Phase 2 Study Investigators
Lancet Neurol. 2017. 16(7):513-522.
This phase 2 randomised, double-blind, placebo-controlled study was done in 22 neuromuscular care centres from 7 european country aimed to study safety and efficacy of olesoxime in patients aged 3-25 years with type 2 or type 3 SMA.
The primary outcome measure was change from baseline compared with 24 months of MFM D1+D2 scores.
Olesoxime seemed to be safe and generally well tolerated at the doses studied. Results suggested that olesoxime might maintain motor function in patients with type 2 or type 3 SMA over a period of 24 months
Keywords: Spinal Muscular atrophy, Phase 2, Safety, Olesoxime
Articles dans les revues scientifiques
Improvements in motor tasks through the use of smartphone technology for individuals with Duchenne muscular dystrophy
Capelini CM, da Silva TD, Tonks J, Watson S, Alvarez MPB, de Menezes LDC, Favero FM, Caromano FA, Massetti T, de Mello Monteiro CBNeuropsychiatr Dis Treat. 2017. 18(13):2209-2217. L'objectif principal de l'étude était de vérifier si des sujets atteints de la...
Long-term follow-up of MRI changes in thigh muscles of patients with Facioscapulohumeral dystrophy: A quantitative study
Fatehi F, Salort-Campana E, Le Troter A, Lareau-Trudel E, Bydder M, Fouré A, Guye M, Bendahan D, Attarian S PLoS One. 2017 Aug 25;12(8):e0183825. L'objectif principal de l'étude était d'étudier longitudinalement les changements qui se produisent dans les muscles de la...
Patients with Duchenne and Becker muscular dystrophies are not more asymmetrical than healthy controls on timed performance of upper limb tasks
Artilheiro MC, Sá CSC, Fávero FM, Caromano FA, Voos MC. Braz J Med Biol Res. 2017. 50(8): e6031. Cette étude visait à étudier les asymétries possibles et les relations entre la performance des membres supérieurs dominants et non dominants chez les patients atteints de...
Reliability and validity analyses of the North Star Ambulatory Assessment in Brazilian Portuguese
Okama LO, Zampieri LM, Ramos CL, Toledo FO, Alves CRJ, Mattiello-Sverzut AC, Mayhew A, Sobreira CFR Neuromuscul Disord. 2017. 27(8):723-729. Etude de validation de l'adaptation interculturelle en portugais de la North Star Ambulatory Assessment.Une corrélation...
Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III
Kölbel H, Hauffa BP, Wudy SA, Bouikidis A, Della Marina A, Schara U PLoS One. 2017. 9;12(3):e0173144. Etude de la prévalence de l'hyperleptinémie dans une population d'Amyotrophie Spinale Infantile (ASI).La prévalence de l'hyperleptinémie est élevée chez les patients...
Electrical impedance myography (EIM) in individuals with COL6 and LAMA2 congenital muscular dystrophy: a cross-sectional and two-year analysis
Nichols C, Jain MS, Meilleur KG, Wu T, Collins J, Waite MR, Dastgir J, Salman A, Donkervoort S, Duong T, Keller K, Leach ME, Lott DJ, McGuire MN, Nelson L, Rutkowski A, Vuillerot C, Bönnemann CG, Lehky TJ. Muscle Nerve. 2018. 57(1):54-60. L'objectif de cette étude...